polymerization in comparison to the α‐diimine nickel catalyst. Increasing the steric hindrance of the α‐diamine ligand by substitution of the o‐methyl groups with o‐isopropyl groups leads to decreased polymerization activity and molecular weight; however, catalyst thermal stability is significantly enhanced. Living polymerizations of ethylene can be successfully achieved using 1/Et2AlCl at 35 °C or 2/Et2AlCl
一系列新颖α二胺镍络合物,(ArNH-C(Me)的- (Me)的C-NHAr)NIBR 2,1:Ar为2,6-二异丙基,2:Ar为2,6-二甲基苯基,3: Ar =苯基)已经合成并表征。X射线晶体学分析表明,α-二胺镍配合物的配位几何形状与常规α-二亚胺镍配合物显着不同,并且α-二胺镍的螯合环(NC-C-N-Ni)复杂程度明显失真。与α-二亚胺镍催化剂相比,α-二胺镍催化剂对乙烯聚合也显示出不同的空间效应。由取代增加α二胺配位体的空间位阻ö与甲基组ö异丙基会降低聚合活性和分子量;然而,催化剂的热稳定性显着提高。使用1 / Et 2 AlCl在35°C或2 / Et 2 AlCl在0°C可以成功地实现乙烯的活性聚合。具有异丙基取代基的庞大的α-二胺镍催化剂1还可用于通过调节反应温度和乙烯压力,在相同的支化密度水平下控制所得聚乙烯的支化拓扑。
Metal complex and organic letroluminescent devices
申请人:Kobayashi Satoshi
公开号:US20050147843A1
公开(公告)日:2005-07-07
A metal complex which has a metal complex structure showing light emission from triplet excited state, and has a monovalent group derived from carbazole, and a light-emitting device using said metal complex.
A pharmaceutical composition is provided that has a low toxicity, demonstrates superior physicochemical properties and pharmacokinetics, and has superior peripheral blood lymphocyte count lowering activity. The pharmaceutical composition contains a compound having general formula (I):
[Chemical Formula 1]
(wherein R
1
represents a methyl group or an ethyl group, R
2
represents a methyl group or an ethyl group, and R
3
represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.
METAL COMPLEX AND ORGANIC ELETROLUMINESCENT DEVICE
申请人:KOBAYASHI Satoshi
公开号:US20110227050A1
公开(公告)日:2011-09-22
A metal complex which has a metal complex structure showing light emission from triplet excited state, and has a monovalent group derived from carbazole, and a light-emitting device using said metal complex.
A pharmaceutical composition is provided that has a low toxicity, demonstrates superior physicochemical properties and pharmacokinetics, and has superior peripheral blood lymphocyte count lowering activity.
The pharmaceutical composition contains a compound having general formula (I):
(wherein R1 represents a methyl group or an ethyl group, R2 represents a methyl group or an ethyl group, and R3 represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.